SCHEMBL7652407

SCHEMBL7652407

Nc1ccc(-c2nc3cc(Br)ccc3[nH]2)cc1N

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 5/20 0.56
MMP2 P08253 4/20 0.56
MMP9 P14780 4/20 0.56
MMP8 P22894 4/20 0.56
ALDH1A1 P00352 8/20 0.54
SMN1; SMN2 Q16637 8/20 0.54
KDM4E B2RXH2 7/20 0.54
MAPT P10636 7/20 0.54
NPC1 O15118 6/20 0.54
RAB9A P51151 6/20 0.54
PKM P14618 3/20 0.54
HPGD P15428 6/20 0.50
NFKB1 P19838 2/20 0.50
NFKB2 Q00653 1/20 0.50
RELA Q04206 1/20 0.50
MEN1 O00255 5/20 0.46
KMT2A Q03164 5/20 0.46
POLB P06746 4/20 0.46
USP2 O75604 4/20 0.46
TP53 P04637 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7652411 0.88 MMP13 (0.73) MMP13MMP2MMP9MMP8ALDH1A1
SCHEMBL6264476 0.84 MMP2 (0.77) MMP13MMP2MMP9MMP8ALDH1A1
SCHEMBL2361964 0.82 ALDH1A1 (0.52) ALDH1A1SMN1; SMN2KDM4EMAPTNPC1
SCHEMBL7652952 0.81 SMN1; SMN2 (0.56) ALDH1A1SMN1; SMN2KDM4EMAPTNPC1
SCHEMBL7653231 0.81 SMN1; SMN2 (0.56) ALDH1A1SMN1; SMN2KDM4EMAPTNPC1
SCHEMBL1170673 0.80 PDPK1 (0.51) MMP13MMP2MMP9MMP8ALDH1A1
SCHEMBL8148043 0.80 NPC1 (0.75) MMP2MMP9MMP8ALDH1A1SMN1; SMN2
SCHEMBL12287266 0.79 ALDH1A1 (0.48) MMP13MMP2MMP9MMP8ALDH1A1
SCHEMBL8130390 0.79 ALDH1A1 (0.54) ALDH1A1SMN1; SMN2KDM4EMAPTNPC1
SCHEMBL7658170 0.79 MMP13 (0.49) MMP13MMP2MMP9MMP8ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6399642-B2 TRIS BENZIMIDAZOLES; FUNGICIDES, ANTICARCINOGENIC AGENTS, ENZYME INHIBITOR RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY 2002-06-04 US disclosed
US-20010009919-A1 Heterocyclic topoisomerase poisons RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY 2001-07-26 US disclosed
US-6221892-B1 Heterocyclic topoisomerase poisons THE STATE OF UNIVERSITY OF NEW JERSEY, RUTGERS 2001-04-24 US disclosed
EP-1054870-A1 HETEROCYCLIC TOPOISOMERASE POISONS RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2000-11-29 EP disclosed
US-6063801-A Heterocyclic topoisomerase poisons RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2000-05-16 US disclosed
WO-1999041241-A1 HETEROCYCLIC TOPOISOMERASE POISONS RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 1999-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010009919-A1 Heterocyclic topoisomerase poisons TOP1, TOP2A, TOP2B MMP13 2829/4885MMP2 2263/4885MMP9 986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.